Show simple item record

Efficacy and tolerability of fixed, low-dose combination therapy with verapamil sustained-release and trandolapril in patients with mild to severe essential hypertension uncontrolled by monotherapy: An open-label, multicenter trial

dc.contributor.authorOflaz, H
dc.contributor.authorBuyukozturk, K
dc.contributor.authorSezer, A
dc.contributor.authorAdalet, K
dc.date.accessioned2021-03-06T11:14:00Z
dc.date.available2021-03-06T11:14:00Z
dc.date.issued2001
dc.identifier.citationAdalet K., Oflaz H., Sezer A., Buyukozturk K., "Efficacy and tolerability of fixed, low-dose combination therapy with verapamil sustained-release and trandolapril in patients with mild to severe essential hypertension uncontrolled by monotherapy: An open-label, multicenter trial", CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL, cilt.62, ss.261-271, 2001
dc.identifier.issn0011-393X
dc.identifier.otherav_ee11371c-615b-4b3f-b5a7-5b9a97d7d5d4
dc.identifier.othervv_1032021
dc.identifier.urihttp://hdl.handle.net/20.500.12627/156297
dc.identifier.urihttps://doi.org/10.1016/s0011-393x(01)80010-2
dc.description.abstractBackground: Only 40% to 60% of patients with essential hypertension respond adequately to antihypertensive monotherapy. The combination of an angiotensin-converting enzyme inhibitor and a calcium antagonist, both of which have tissue-protective properties but different mechanisms of action, may lead to an additive antihypertensive effect.
dc.language.isoeng
dc.subjectDahili Tıp Bilimleri
dc.subjectTıbbi Ekoloji ve Hidroklimatoloji
dc.subjectEczacılık
dc.subjectTemel Eczacılık Bilimleri
dc.subjectYaşam Bilimleri
dc.subjectTemel Bilimler
dc.subjectTıp
dc.subjectSağlık Bilimleri
dc.subjectYaşam Bilimleri (LIFE)
dc.subjectFarmakoloji ve Toksikoloji
dc.subjectFARMAKOLOJİ VE ECZACILIK
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectTIP, ARAŞTIRMA VE DENEYSEL
dc.titleEfficacy and tolerability of fixed, low-dose combination therapy with verapamil sustained-release and trandolapril in patients with mild to severe essential hypertension uncontrolled by monotherapy: An open-label, multicenter trial
dc.typeMakale
dc.relation.journalCURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
dc.contributor.department, ,
dc.identifier.volume62
dc.identifier.issue4
dc.identifier.startpage261
dc.identifier.endpage271
dc.contributor.firstauthorID161623


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record